177Lu-DOTA-EB-FAPI
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for 177Lu-DOTA-EB-FAPI, covering 2025-03-28 to 2025-04-01. Get the full timeline:
Most recent: Clinical Trial Update: Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer [Phase 1]